Red Queen Bio
United StatesIndustry
Red Queen Bio develops AI-enabled biosecurity defences. CBRNE-relevant work is a minor part of its offering according to its website.
What it does
Profile
Red Queen Bio is an AI biosecurity company spun out of HelixNano that uses AI models, laboratory automation and reinforcement learning to identify biological risks and develop defences. OpenAI led its 15 million dollar seed round in November 2025, joined by Cerberus Ventures, Fifty Years and Halcyon Futures, according to Reuters and the law firm that advised it.
More profile
By September 2026 it had raised 36 million dollars in total and was developing AI-designed antiviral antibodies, with first clinical trials planned for 2027. The Wall Street Journal and trade press have described its work on antibodies for future viruses.
Ownership
Privately held, venture-backed; spun out of HelixNano
Parent: HelixNano
Sources (5)
- https://www.reuters.com/technology/openai-backs-startup-aiming-to-block-ai-enabled-bioweapons-2025-11-13/
- https://www.cerberus-ventures.com/perspectives/ai-biosecurity-company-red-queen-bio-launches
- https://thenextweb.com/news/red-queen-bio-ai-antibodies-openai-wsj
- https://mgmtlifesciences.com/news/openai-backed-red-queen-bio-brings-total-funding-to-36m-2026-09-28
- https://www.goodwinlaw.com/en/news-and-events/news/2025/12/announcements-lifesciences-goodwin-advises-red-queen-bio
Not verified or not found
- Founding date and headquarters: not found.
- Clinical trial timing: company plan only.
Questions
What does Red Queen Bio do?
Red Queen Bio develops AI-enabled biosecurity defences. CBRNE-relevant work is a minor part of its offering according to its website.
Where is Red Queen Bio based?
HQ country: US.
Who owns Red Queen Bio?
Privately held, venture-backed; spun out of HelixNano. Parent: HelixNano
Profiles are compiled from public sources and sampled-checked, not fully audited. Last verified 17 October 2026. Report a correction